Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2008

View Archived Issues

Acucela doses first subject in phase I age-related macular degeneration trial

Genetic cause found for X-linked rare inherited disorder causing epilepsy and mental retardation

Gene therapy slows neurological decline in children with neuronal ceroid lipofuscinosis

Protalix to commence open-label extension study for its phase III prGCD trial

Addex commences phase I interaction study with new ADX-10059 formulation

MediGene to focus R&D activities on oncology and immunology fields

GSK exercises right to AM-803 FLAP inhibitor under agreement with Amira

Santen files Japanese manufacturing and marketing approval applications for DE-089

Santen enters agreement in Japan and Asia with MacuSight for sirolimus

Addrenex completes enrollment in U.S. phase III clinical trial of Clonicel in ADHD

Avexa enters collaboration with TargetDrug for novel lead inhibitors of HCV replication

Nabi receives a USD 2.5 million milestone payment from Fresenius for CARE-2 study

Callisto commences phase I trial for constipation and IBD candidate SP-304

NIAID initiates phase I safety study of Avant's oral ETEC-Cholera vaccine

Astra Zeneca reports on novel GABA-B agonist candidate for reflux treatment

Positive first-in-human results for novel multi-CDK inhibitor PHA-848125

Kyowa Hakko and Kyorin terminate collaborative marketing agreement for Allelock

Tripep reports positive results from ongoing study of ChronVac-C HCV therapeutic vaccine

Novartis acquires Protez and North American and European rights to PZ-601 antibiotic

CHMP issues positive opinion for antibacterial agent Doribax

Emergent BioSolutions initiates phase II trial for oral typhoid vaccine candidate

Pharmacopeia identifies new lead compound for advancement under collaboration with GSK

Recent Purdue Pharma and Neuro Therapeutics patents describe novel analgesic agents

Recent Biostatin patent discloses novel agents for treating chronic wounds

New treatment options for gastrointestinal disorders described in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...